EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
作者： Zhiyong Liang , Ying Cheng , Yuan Chen , Yanping Hu , Wei-Ping Liu
DOI: 10.1016/J.CANLET.2017.06.008
关键词: Mutation (genetic algorithm) 、 Tyrosine-kinase inhibitor 、 Precision medicine 、 Germline mutation 、 Internal medicine 、 Tyrosine kinase 、 T790M 、 Oncology 、 Bioinformatics 、 Genetic testing 、 Epidermal growth factor receptor 、 Medicine
摘要: Somatic mutation in the epidermal growth factor receptor (EGFR) predict clinical response to EGFR tyrosine kinase inhibitors non-small cell lung cancer (NSCLC) and is a promising target for personalised medicine. mutations have prognostic value. Initially patients respond well but finally they would develop resistance about 50% of this can be attributed emergence resistant mutation, T790M. This necessitates need genetic testing management patients. Molecular has become standard care with NSCLCs based on recommendations guidelines. Though there are several platforms detection, highly sensitive applicability as companion diagnostics ctDNA emerging. Due dynamic changes T790M during inhibitor (TKI) treatment, real-time monitoring these alterations mandate planning treatment strategies. With advent third generation TKIs that potentially T790M, improvement outcome documented NSCLCs. Managing outcomes appropriate using early detection will improve patient care.
pubmed.cn参考文章(93)
Qing Xu, Mao Mao, Guangjuan Zheng, Yazhen Zhu, Xirun Zheng, Yali Bai, Xiumin Wei, Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. OncoTargets and Therapy. ,vol. 8, pp. 1533- 1541 ,(2015) , 10.2147/OTT.S84938
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854
Glenn Francis, Sandra Stein, Circulating Cell-Free Tumour DNA in the Management of Cancer International Journal of Molecular Sciences. ,vol. 16, pp. 14122- 14142 ,(2015) , 10.3390/IJMS160614122
Helena A. Yu, Shaozhou K. Tian, Alexander E. Drilon, Laetitia Borsu, Gregory J. Riely, Maria E. Arcila, Marc Ladanyi, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain JAMA Oncology. ,vol. 1, pp. 982- 984 ,(2015) , 10.1001/JAMAONCOL.2015.1066
Boe S. Sorensen, Lin Wu, Wen Wei, Julie Tsai, Britta Weber, Ebba Nexo, Peter Meldgaard, Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor‐sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib Cancer. ,vol. 120, pp. 3896- 3901 ,(2014) , 10.1002/CNCR.28964
Yuliana Yosaatmadja, Shevan Silva, James M. Dickson, Adam V. Patterson, Jeff B. Smaill, Jack U. Flanagan, Mark J. McKeage, Christopher J. Squire, Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology. ,vol. 192, pp. 539- 544 ,(2015) , 10.1016/J.JSB.2015.10.018
Hidenobu Ishii, Koichi Azuma, Kazuko Sakai, Akihiko Kawahara, Kazuhiko Yamada, Takaaki Tokito, Isamu Okamoto, Kazuto Nishio, Tomoaki Hoshino, Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples Oncotarget. ,vol. 6, pp. 30850- 30858 ,(2015) , 10.18632/ONCOTARGET.5068
Antonio Marchetti, Maela Del Grammastro, Lara Felicioni, Sara Malatesta, Giampaolo Filice, Irene Centi, Tommaso De Pas, Armando Santoro, Antonio Chella, Alba Ariela Brandes, Paola Venturino, Franco Cuccurullo, Lucio Crinò, Fiamma Buttitta, Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0103883
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Journal of Thoracic Oncology. ,vol. 8, pp. 823- 859 ,(2013) , 10.1097/JTO.0B013E318290868F
Jean-Yves Douillard, Gyula Ostoros, Manuel Cobo, Tudor Ciuleanu, Rebecca Cole, Gael McWalter, Jill Walker, Simon Dearden, Alan Webster, Tsveta Milenkova, Rose McCormack, Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status Journal of Thoracic Oncology. ,vol. 9, pp. 1345- 1353 ,(2014) , 10.1097/JTO.0000000000000263